This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV)

Tipranks - Tipranks - Wed Jun 17, 6:04AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV).

Claim 55% Off TipRanks

enGene Holdings (ENGN)

In a report released today, Michael Schmidt from Guggenheim maintained a Hold rating on enGene Holdings. The company’s shares closed last Monday at $1.77.

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 28.4% and a 53.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, ArriVent BioPharma, Inc., and Monte Rosa Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for enGene Holdings with a $5.64 average price target, implying a 222.3% upside from current levels. In a report issued on June 11, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $1.50 price target.

See today’s best-performing stocks on TipRanks >>

Medtronic (MDT)

In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Medtronic, with a price target of $85.00. The company’s shares closed last Monday at $80.38.

According to TipRanks.com, O’Brien is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 35.5% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $97.52 average price target, which is a 21.5% upside from current levels. In a report issued on June 1, TipRanks – OpenAI also downgraded the stock to Hold with a $80.00 price target.

Roivant Sciences (ROIV)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00. The company’s shares closed last Monday at $30.03.

According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 27.4% and a 44.3% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, NewAmsterdam Pharma Company, and Praxis Precision Medicines. ;'>

Roivant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $36.53.

Read More on ENGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).